Stocks and Investing
by (remove) : Phil Nadeau
RSSJSONXMLCSV
Stocks and Investing
by (remove) : Phil Nadeau
RSSJSONXMLCSV
Tue, August 6, 2024
Tue, July 23, 2024
Wed, August 2, 2023
Wed, June 28, 2023
Tue, May 2, 2023
Thu, February 16, 2023
Fri, October 28, 2022
Thu, July 21, 2022
Mon, June 13, 2022
Tue, November 23, 2021
Thu, October 21, 2021
Mon, November 9, 2020
Tue, August 18, 2020
Wed, October 23, 2019
Wed, July 19, 2017

Phil Nadeau Maintained (BMRN) at Strong Buy with Decreased Target to $120 on, Aug 6th, 2024


Published on 2024-10-28 13:16:23 - WOPRAI, Phil Nadeau
  Print publication without navigation


Phil Nadeau of TD Cowen, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Decreased Target from $125 to $120 on, Aug 6th, 2024.

Phil has made no other calls on BMRN in the last 4 months.



There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 3 agree with Phil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold and Held Target at $89 on, Thursday, July 25th, 2024
  • Joel Beatty of "Baird" Downgraded from Buy to Hold and Decreased Target to $72 on, Friday, May 17th, 2024
  • David Lebovitz of "Citigroup" Maintained at Hold with Decreased Target to $91 on, Thursday, April 25th, 2024


These are the ratings of the 3 analyists that currently disagree with Phil


  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Monday, August 5th, 2024
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $115 on, Thursday, June 27th, 2024
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $112 on, Friday, April 26th, 2024
Contributing Sources